CLVLY

Clinuvel Pharmaceuticals Limited [CLVLY] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CLVLY Stock Summary

Top 10 Correlated ETFs

CLVLY

Top 10 Correlated Stocks

CLVLY

In the News

CLVLY Financial details

Company Rating
-
Market Cap
490.24M
Income
56.55M
Revenue
151.67M
Book val./share
-
Cash/share
-
Dividend
0.03
Dividend %
0.2%
Employees
-
Optionable
No
Shortable
Yes
Earnings
28 Aug 2024
P/E
26.79
Forward P/E
-
PEG
1.56
P/S
10.13
P/B
4.98
P/C
-
P/FCF
22.11
Quick Ratio
7.02
Current Ratio
7.44
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
1.14
EPS next Y
-
EPS next Q
-
EPS this Y
47.62%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
10.29%
Revenue last 5Y
20.33%
Revenue Q/Q
-34.12%
EPS Q/Q
-43.59%
-
-
-
-
SMA20
14.29%
SMA50
14.29%
SMA100
14.29%
Inst Own
-
Inst Trans
-
ROA
16%
ROE
22%
ROC
0.26%
Gross Margin
90%
Oper. Margin
56%
Profit Margin
39%
Payout
6%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.54-13.97
52W High
-39.38%
52W Low
-1.5%
RSI
48
Rel Volume
0.13
Avg Volume
3.74K
Volume
498
Perf Week
1.29%
Perf Month
22.74%
Perf Quarter
10.67%
Perf Half Y
9.6%
-
-
-
-
Beta
0.744
-
-
Volatility
0.37%, 0.43%
Prev Close
5.91%
Price
7.88
Change
-1.5%

CLVLY Financial Performance

CLVLY Dividend History

CLVLY Frequently Asked Questions

What is Clinuvel Pharmaceuticals Limited stock symbol ?

Clinuvel Pharmaceuticals Limited is a AU stock , located in Melbourne of Vic and trading under the symbol CLVLY

What is Clinuvel Pharmaceuticals Limited stock quote today ?

Clinuvel Pharmaceuticals Limited stock price is $7.88 today.

Is Clinuvel Pharmaceuticals Limited stock public?

Yes, Clinuvel Pharmaceuticals Limited is a publicly traded company.

Something similar

Top by Market Cap
0YXG.L
AMZN
VFINX
BRK-A
GOOGL
Top Correlated ETFs
KURE
CASE.L
CNUA.L
CNAL.L
CNAA.DE
Top Correlated Stocks
1167.HK
2216.HK
2160.HK
0858.HK
601208.SS
Similar Market Cap
2B7D.DE
600139.SS
2000.HK
0922.HK
MTDB.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 3.74K
  • Market Capitalization 490.24M
  • CEO Dr. Philippe Jacques Wolgen M.B.A., M.D.
  • Headquarters Melbourne,VIC,AU
  • IPO Date 2008-01-30
  • Website https://www.clinuvel.com

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.